Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113

Journal of Clinical Oncology

Volumn 26, Issue 28, 2008, Pages 4551-4556

  Ajani, Jaffer A ^a   Winter, Kathryn ^a   Komaki, Ritsuko ^a   Kelsen, David P ^a   Minsky, Bruce D ^a   Liao, Zhongxing ^a   Bradley, Jeffrey ^a   Fromm, Mitchel ^a   Hornback, David ^a   Willett, Christopher G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALLERGY; ARTICLE; BONE DISEASE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; ESOPHAGUS CARCINOMA; ESOPHAGUS DISEASE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL INFECTION; HEARING DISORDER; HEART ARRHYTHMIA; HUMAN; HUMAN TISSUE; LARYNX DISORDER; LIVER TOXICITY; LUNG TOXICITY; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; ONCOLOGY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SAFETY; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; UROGENITAL TRACT DISEASE; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 53749102232     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.6918     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
3. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142-146, 2005
4. Enzinger PC, Mayer R: Esophageal cancer. N Engl J Med 349:2241-2252, 2003
5. Bosset JF, Gignoux M, Triboulet JP, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337:161-167, 1997
6. Burmeister BH, Smithers BM, Gebski V, et al: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol 6:659-668, 2005
7. Kelsen DP: Multimodality therapy of local regional esophageal cancer. Semin Oncol 32:S6-S10, 2005 (suppl 9)
8. Urba SG, Orringer MB, Turrisi A, et al: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305-313, 2001
9. Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26:1086-1092, 2008. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrive&db= PubMed&dopt=Citation&list_uids=18309943
10. Gebski V, Burmeister B, Smithers BM, et al: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 8:226-234, 2007
11. Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01) - Radiation Therapy Oncology Group. JAMA 281:1623-1627, 1999
12. Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167-1174, 2002
13. Ilson DH, Ajani J, Bhalla K, et al: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16:1826-1834, 1998
14. Ajani JA, Ilson DH, Kelsen DP: Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Semin Oncol 23:55-58, 1996
15. Ajani JA, Ilson DH, Daugherty K, et al: Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086-1091, 1994
16. Sinclair WK, Morton RA: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29:450-474, 1966
17. Terasima T, Tolmachi LJ: X-ray sensitivity and DNA synthesis in synchronized populations of HeLa cells. Science 140:490-492, 1963
18. Choy H, Akerley H, Safran H, et al: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol 12:2682-2686, 1994
19. Schnirer II, Komaki R, Yao JC, et al: Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol 24:91-95, 2001
20. Brenner B, Ilson DH, Minsky BD, et al: Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 22:45-52, 2004
21. Dixon DO, Simon R: Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol 41:1209-1213, 1988
22. Zelen M: The randomization and stratification of patients to clinical trials. J Chron Dis 27:365-375, 1974
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
25. Kleinberg L, Forastiere AA: Chemoradiation in the management of esophageal cancer. J Clin Oncol 25:4110-4117, 2007
26. Urba S: Combined modality therapy of esophageal cancer: Standard of care? Surg Oncol Clin N Am 11:377-386, 2002
27. Ajani J, Bekaii-Saab T, D'Amico TA, et al: Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 4:328-347, 2006
28. Das P, Fukami N, Ajani JA: Combined modality therapy of localized gastric and esophageal cancers. J Natl Compr Canc Netw 4:375-382, 2006